These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 20609175)

  • 41. [Immunmodulatory antibodies in the treatment of skin cancer].
    Schrama D; Hauschild A; Becker JC
    Hautarzt; 2008 Oct; 59(10):806-13. PubMed ID: 18777167
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunotherapy toxicity predicted by circulating cytokines.
    Gourd E
    Lancet Oncol; 2018 Dec; 19(12):e676. PubMed ID: 30449658
    [No Abstract]   [Full Text] [Related]  

  • 43. NICE approves immunotherapy combination for advanced melanoma.
    Wise J
    BMJ; 2016 Jun; 353():i3421. PubMed ID: 27317590
    [No Abstract]   [Full Text] [Related]  

  • 44. Combined immunotherapy improves survival in metastatic melanoma.
    Mayor S
    BMJ; 2015 Jun; 350():h2993. PubMed ID: 26036979
    [No Abstract]   [Full Text] [Related]  

  • 45. Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center.
    Stenehjem DD; Au TH; Ngorsuraches S; Ma J; Bauer H; Wanishayakorn T; Nelson RS; Pfeiffer CM; Schwartz J; Korytowsky B; Oderda G; Brixner DI
    Melanoma Res; 2019 Dec; 29(6):626-634. PubMed ID: 30688762
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Emerging strategies for the treatment of metastatic melanoma: the role of monoclonal antibodies in targeted immunotherapy. Introduction.
    Trinh VA; Poust J
    Am J Health Syst Pharm; 2008 Dec; 65(24 Suppl 9):S1-2. PubMed ID: 19052262
    [No Abstract]   [Full Text] [Related]  

  • 47. Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease.
    Pedersen M; Andersen R; Nørgaard P; Jacobsen S; Thielsen P; Thor Straten P; Svane IM
    Cancer Immunol Immunother; 2014 Dec; 63(12):1341-6. PubMed ID: 25227926
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of interferon in melanoma: old hopes and new perspectives.
    Sanlorenzo M; Vujic I; Carnevale-Schianca F; Quaglino P; Gammaitoni L; Fierro MT; Aglietta M; Sangiolo D
    Expert Opin Biol Ther; 2017 Apr; 17(4):475-483. PubMed ID: 28274138
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug development: Releasing the brakes.
    Weintraub K
    Nature; 2013 Dec; 504(7480):S6-8. PubMed ID: 24352363
    [No Abstract]   [Full Text] [Related]  

  • 50. Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma.
    de Greef R; Elassaiss-Schaap J; Chatterjee M; Turner DC; Ahamadi M; Forman M; Cutler D; de Alwis DP; Kondic A; Stone J
    CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):5-7. PubMed ID: 27653180
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Melanoma and a Headache. Diagnosis: Hypophysitis.
    Johnson DB; Mudigonda TV; Sosman JA
    JAMA Oncol; 2015 Nov; 1(8):1167-8. PubMed ID: 26225893
    [No Abstract]   [Full Text] [Related]  

  • 52. Utilization of immunotherapy among patients with stage 4 melanoma: An analysis of the National Cancer Database from 2012 to 2016.
    Shah PV; Choi JN; Fiessinger L; Nardone B; Nguyen CV; Liszewski W
    J Am Acad Dermatol; 2021 Mar; 84(3):811-814. PubMed ID: 32553633
    [No Abstract]   [Full Text] [Related]  

  • 53. [How to choose the optimal therapy? New issues in the treatment of metastatic melanoma].
    Oláh J; Gyulai R
    Magy Onkol; 2016 Mar; 60(1):17-21. PubMed ID: 26934346
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunotherapy and Oncogenic Pathways: The PTEN Connection.
    Rizvi NA; Chan TA
    Cancer Discov; 2016 Feb; 6(2):128-9. PubMed ID: 26851183
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adoption of ipilimumab in the United States: a Medicare study.
    Yao N; Jang S
    Expert Rev Pharmacoecon Outcomes Res; 2016 Aug; 16(4):439-40. PubMed ID: 27097117
    [No Abstract]   [Full Text] [Related]  

  • 56. Adjuvant Ipilimumab for Melanoma-The $1.8 Million per Patient Regimen.
    Goldstein DA
    JAMA Oncol; 2017 Dec; 3(12):1628-1629. PubMed ID: 28983562
    [No Abstract]   [Full Text] [Related]  

  • 57. Tumour immunology: Microbiota predicts side-effects of immunotherapy.
    Bordon Y
    Nat Rev Immunol; 2016 Mar; 16(3):130-1. PubMed ID: 26875828
    [No Abstract]   [Full Text] [Related]  

  • 58. Antibody-drug conjugate for advanced melanoma?
    Sharma SP
    Lancet Oncol; 2014 Nov; 15(12):e534. PubMed ID: 25602109
    [No Abstract]   [Full Text] [Related]  

  • 59. Immune and toxic anti-tumor effects of systemic and intralesional vitamin A.
    Felix EL; Cohen MH; Loyd BC
    J Surg Res; 1976 Nov; 21(5):307-12. PubMed ID: 1003960
    [No Abstract]   [Full Text] [Related]  

  • 60. Feasibility of immunotherapy for lymphangioleiomyomatosis.
    Carbone M
    Am J Pathol; 2009 Dec; 175(6):2252-4. PubMed ID: 19893040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.